<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401527</url>
  </required_header>
  <id_info>
    <org_study_id>SN02-01</org_study_id>
    <nct_id>NCT04401527</nct_id>
  </id_info>
  <brief_title>Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite</brief_title>
  <official_title>Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hope Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate&#xD;
      the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients&#xD;
      infected with COVID-19 who develop lung injury and require mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial will&#xD;
      evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of&#xD;
      patients infected with COVID-19 who develop lung injury and require mechanical ventilation.&#xD;
      The primary objective is to compare the two treatment groups with respect to the proportion&#xD;
      of study subjects who are alive and free of respiratory failure at Day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Actual">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival with Unassisted Breathing</measure>
    <time_frame>Day 28</time_frame>
    <description>Proportion of study subjects who are alive and free of respiratory failure at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without Mechanical Ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive without mechanical ventilation from start of study through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without Intensive Care</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive and not in the intensive care unit from start of study through Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without Hospitalization</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive and not in hospital from start of study through Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without ECMO</measure>
    <time_frame>Day 28</time_frame>
    <description>Alive on Day 28 and no use of ECMO therapy any time between start of study and Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Day 28</time_frame>
    <description>Alive on Day 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lung Status</measure>
    <time_frame>Day 14</time_frame>
    <description>Oxygenation index (PaO2/FIO2) at Day 14</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Status (1)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood urea nitrogen (BUN) at Day 14</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Status (2)</measure>
    <time_frame>Day 14</time_frame>
    <description>Creatinine at Day 14</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver Status</measure>
    <time_frame>Day 14</time_frame>
    <description>Liver function tests (ALT and AST) at Day 14</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite</intervention_name>
    <description>Continuous intravenous infusion of Sodium Nitrite Injection</description>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <other_name>Hope Pharmaceuticals Sodium Nitrite Injection USP 30 mg/mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Continuous intravenous infusion of Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older;&#xD;
&#xD;
          2. Diagnosed COVID-19 disease with confirmed SARS-coV-2 viral infection;&#xD;
&#xD;
          3. Able to sign the informed consent form (ICF) or next of kin/legal guardian able to&#xD;
             sign informed consent;&#xD;
&#xD;
          4. Randomization within 24 hours of intubation and mechanical ventilation due to&#xD;
             respiratory failure from COVID-19 infection;&#xD;
&#xD;
          5. Absolute lymphocyte count &gt; 800 / mm3;&#xD;
&#xD;
          6. Women of childbearing potential (WCBP) must have a negative urine or serum (if anuric)&#xD;
             pregnancy test at screening;&#xD;
&#xD;
          7. WCBP must agree to abstain from sex or use an adequate method of contraception from&#xD;
             the time of informed consent through Day 28;&#xD;
&#xD;
          8. Males must abstain from sex with WCBP or use an adequate method of contraception from&#xD;
             the time of informed consent through Day 28.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Methemoglobinemia &gt; 2%;&#xD;
&#xD;
          2. Hypotension with systemic blood pressure &lt; 90/60 mm Hg, or uncontrolled hypotension&#xD;
             despite vasopressor support;&#xD;
&#xD;
          3. History of sickle cell disease, thalassemia, G6PD deficiency, lung transplant, or&#xD;
             allergy to sodium nitrite;&#xD;
&#xD;
          4. Hemoglobin &lt; 8 gm/dL;&#xD;
&#xD;
          5. Renal impairment with creatinine clearance &lt; 60 mL/min/1.73m2;&#xD;
&#xD;
          6. Treatment within the past 48 hours with allopurinol (a medication that could interfere&#xD;
             with nitrite metabolism);&#xD;
&#xD;
          7. Treatment within the past 24 hours with organic nitrates such as nitroglycerin,&#xD;
             isosorbide mononitrate, isosorbide dinitrate, sodium nitroprusside, and inhaled nitric&#xD;
             oxide;&#xD;
&#xD;
          8. Treatment within the past 24 hours with lidocaine, prilocaine, benzocaine, and&#xD;
             dapsone;&#xD;
&#xD;
          9. Requiring extracorporeal membrane oxygenation (ECMO);&#xD;
&#xD;
         10. Subjects with bacterial or fungal infections except for mild cutaneous infections or&#xD;
             sinus infections;&#xD;
&#xD;
         11. Subjects who are pregnant or lactating;&#xD;
&#xD;
         12. Any condition that, in the opinion of the Investigator, places the subject at&#xD;
             unacceptable risk if he/she were to participate in the study;&#xD;
&#xD;
         13. Clinically relevant serious co-morbid medical conditions including, but not limited&#xD;
             to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension,&#xD;
             uncontrolled cardiac arrhythmias, uncontrolled chronic obstructive or chronic&#xD;
             restrictive pulmonary disease, active central nervous system (CNS) disease&#xD;
             uncontrolled by standard of care, known positive status for human immunodeficiency&#xD;
             virus (HIV) (except if HIV subject has undetectable viral load and a CD4 count of ≥&#xD;
             500 cells/µL), and/or active hepatitis B or C, cirrhosis, or uncontrolled psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements;&#xD;
&#xD;
         14. Treatment within 30 days or 5 half-lives of that agent (whichever is shorter) before&#xD;
             the first study drug dose using another investigational drug. Notwithstanding,&#xD;
             prospective subjects who receive any of the following drugs or treatments before the&#xD;
             first study drug dose or during this study may be considered for participation in this&#xD;
             study: (1) a commercially available, FDA-approved drug or treatment used off-label for&#xD;
             the treatment of COVID-19, or (2) a drug or treatment that has FDA Emergency Use&#xD;
             Authorization for the treatment of COVID-19 patients;&#xD;
&#xD;
         15. Moribund or not expected to survive 48 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope Pharmaceuticals Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Hope Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Participating Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Participating Research Facility</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Acute Respiratory Failure</keyword>
  <keyword>ARDS</keyword>
  <keyword>Respiratory Failure</keyword>
  <keyword>Intubation</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Intubated</keyword>
  <keyword>Mechanical Ventilator</keyword>
  <keyword>ECMO</keyword>
  <keyword>Sodium Nitrite</keyword>
  <keyword>Nitrite</keyword>
  <keyword>Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

